What are the causes of low gamma-glutamyl transferase (GGT) cholestasis?

Causes of Low GGT Cholestasis

Low GGT cholestasis is primarily caused by genetic defects in bile acid transporters, tight junction proteins, bile acid synthesis enzymes, and nuclear receptors—most commonly PFIC types 1 and 2, bile acid synthesis disorders, and tight junction protein deficiencies.

Primary Genetic Causes

The most comprehensive classification comes from hereditary cholestatic liver disease guidelines, which categorize low-GGT cholestasis into distinct functional groups 1:

Bile Acid and Phospholipid Transporters

• ABCB11 (BSEP) mutations - Causes PFIC type 2, BRIC, and intrahepatic cholestasis of pregnancy 1, 2
• ATP8B1 (FIC1) mutations - Causes PFIC type 1 (formerly Byler disease), BRIC, and Greenland familial cholestasis 1

These represent the most common genetic causes of low-GGT cholestasis, with PFIC disorders having an estimated incidence of 1 per 50,000 to 100,000 live births 1.

Tight Junction Protein Defects

• TJP2 (ZO-2) mutations - Causes hypercholanemia with characteristic elongated hepatocyte-hepatocyte tight junctions 1
• USP53 mutations - Recently identified cause producing a partial phenocopy of TJP2 disease, with transient cholestasis typically resolving by age 5 years 3
• CLDN1 mutations - Associated with ILVASC/NISCH syndrome 1

Bile Acid Synthesis Disorders (BASDs)

These are particularly important because they are treatable forms of cholestasis 1. Key features include:

• Normal or low total bile acids (0-10 μmol/L) 4
• Low or normal GGT levels 1
• Treatable with cholic acid and chenodeoxycholic acid supplementation 1

Specific genes involved:

• BAAT - Bile acid conjugation enzyme deficiency 1
• SLC27A5 - BACL deficiency 1
• HSD3B7 - Bile acid synthesis defect 5

Nuclear Receptor Defects

• NR1H4 (FXR) mutations - Associated with intrahepatic cholestasis of pregnancy and progressive cholestasis 1

Metabolic and Endocrine Causes

Classic Galactosemia

Recent evidence demonstrates that classic galactosemia consistently presents with low GGT cholestasis 6. This is critical because:

• Prompt cessation of galactose intake can be lifesaving
• GGT rises after initiation of galactose-free diet, possibly due to normalization of bile acid transporter glycosylation 6
• Should be considered in all neonatal low-GGT cholestasis cases 6

Citrin Deficiency

• SLC25A13 mutations - Accounts for approximately 10.4% of intrahepatic cholestasis cases in some series 7

Endocrine Disorders

• Hypopituitarism (some forms) 6
• Typically present with hypoglycemia and preserved liver synthetic function 4

Other Important Causes

Gestational Alloimmune Liver Disease (GALD)

• Presents with markedly elevated ferritin (median 2098 μg/L) 4
• Very high AFP levels (median 22,566 ng/mL) 4

Mitochondrial Hepatopathies

• DGUOK mutations 5
• Elevated plasma lactate (median 5.8 mmol/L) 4
• Markedly elevated AFP (median 99,637 ng/mL) 4

Diagnostic Algorithm

When encountering low-GGT cholestasis, follow this systematic approach:

1. Measure total bile acids: Normal or very low levels (0-10 μmol/L) strongly suggest bile acid synthesis disorders 4

2. Check for metabolic red flags:

   • Ferritin >2000 μg/L → Consider GALD or HLH 4
   • Lactate >5 mmol/L → Consider mitochondrial disease 4
   • AFP >20,000 ng/mL → Consider mitochondrial disease, tyrosinemia, or GALD 4
   • Hypoglycemia with preserved synthetic function → Consider metabolic/endocrine causes 4

3. Perform targeted genetic testing: Gene panel testing should include ABCB11, ATP8B1, TJP2, USP53, NR1H4, and bile acid synthesis genes 1, 5

4. Consider galactosemia screening: All neonates with low-GGT cholestasis should have galactosemia excluded immediately 6

Critical Clinical Pearls

About 30% of patients with a PFIC phenotype have no mutations in known genes 1, warranting whole exome sequencing in unexplained cases.

GGT levels ≤75 U/L have 100% sensitivity for predicting poor prognosis in infantile cholestasis, though specificity is only 43.3% 7. These patients require aggressive early investigation.

BSEP deficiency (PFIC type 2) carries significant HCC risk: Patients with biallelic protein-truncating mutations have approximately 15% incidence of HCC before age 5 years 2. HCC screening with AFP and ultrasound every 3-6 months is mandatory from diagnosis onwards 2.

Consanguinity is noted in 56% of genetically diagnosed cases 5, making family history crucial in the diagnostic workup.

The distinction between low and high GGT cholestasis is fundamental: high-GGT cholestasis points toward biliary obstruction, Alagille syndrome, ciliopathies, and mitochondrial hepatopathies, while low-GGT cholestasis indicates the genetic and metabolic causes outlined above 4, 5.